FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2171736612> ?p ?o ?g. }

• W2171736612 endingPage "239" @default.
• W2171736612 startingPage "227" @default.
• W2171736612 abstract "Study Objective To characterize the effects of two doses (10 and 60 mg) of lomitapide—a microsomal triglyceride transfer protein inhibitor approved as adjunct treatment to lower low‐density lipoprotein cholesterol levels in patients with homozygous familial hypercholesterolemia—on the pharmacokinetics of several lipid‐lowering therapies: atorvastatin, simvastatin, rosuvastatin, fenofibrate, ezetimibe, and niacin. Design Two prospective open‐label studies (study 1 and study 2). Setting Two clinical research units. Subjects A total of 130 healthy volunteers (114 subjects in study 1 and 16 subjects in study 2). Intervention In study 1, subjects were enrolled sequentially to one of the following eight open‐label treatment arms (probe drug + lomitapide): atorvastatin 20 mg + lomitapide 10 mg, atorvastatin 20 mg + lomitapide 60 mg, simvastatin 20 mg + lomitapide 10 mg, rosuvastatin 20 mg + lomitapide 10 mg, rosuvastatin 20 mg + lomitapide 60 mg, fenofibrate 145 mg + lomitapide 10 mg, ezetimibe 10 mg + lomitapide 10 mg, and extended‐release niacin 1000 mg + lomitapide 10 mg. Study 2 consisted of the ninth treatment arm: simvastatin 40 mg + lomitapide 60 mg. Subjects received one dose of the probe drug on the morning of day 1. On days 2–7, subjects took their dose of lomitapide once/day in the morning. On day 8, subjects received one dose of lomitapide simultaneously with the same probe drug they took on day 1. Subjects returned 1 week later (day 15) for a final visit to check safety laboratory parameters. Measurements and Main Results A full pharmacokinetic profile was performed for the probe drug on day 1 and day 8 (after 7 days of dosing with lomitapide [i.e., at steady state]). Pharmacokinetic parameters were calculated from the plasma concentration‐time data for each day by using noncompartmental methods. Analysis of variance was applied to the ln‐transformed maximum concentration (C max ) and area under the plasma concentration‐time curve from time 0–t ( AUC 0–t ) values, and ratios of the means were compared for day 8 versus day 1. Lomitapide increased exposure to the statin medications. The percent least squares means ratios ( LSMR %) (90% confidence intervals [ CIs ]) for AUC 0–t of the statin medications with lomitapide at the 60 mg dose were as follows: 129 (115–144) for the sum of the active atorvastatin moieties, 168 (139–203) for simvastatin acid, and 132 (112–157) for rosuvastatin. The LSMR % (90% CI ) for C max was 138 (120–160) for the sum of the active atorvastatin moieties, 157 (133–186) for simvastatin acid, and 104 (82–32) for rosuvastatin. The LSMR s were not appreciably altered for the other probe drugs. Conclusion This study shows that lomitapide is a weak inhibitor of CYP 3A4 and increased the exposure of statin medications. Careful monitoring of adverse events of CYP 3A4‐metabolized statins should be used when initiating therapy with lomitapide." @default.
• W2171736612 created "2016-06-24" @default.
• W2171736612 creator A5021831441 @default.
• W2171736612 creator A5030855173 @default.
• W2171736612 creator A5037375815 @default.
• W2171736612 creator A5075555151 @default.
• W2171736612 creator A5079278801 @default.
• W2171736612 creator A5086571286 @default.
• W2171736612 creator A5086951622 @default.
• W2171736612 date "2013-10-15" @default.
• W2171736612 modified "2023-10-16" @default.
• W2171736612 title "Pharmacokinetic Interactions of the Microsomal Triglyceride Transfer Protein Inhibitor, Lomitapide, with Drugs Commonly Used in the Management of Hypercholesterolemia" @default.
• W2171736612 cites W1510298788 @default.
• W2171736612 cites W1999262734 @default.
• W2171736612 cites W2006367226 @default.
• W2171736612 cites W2019169107 @default.
• W2171736612 cites W2022507089 @default.
• W2171736612 cites W2027410033 @default.
• W2171736612 cites W2032320739 @default.
• W2171736612 cites W2039688545 @default.
• W2171736612 cites W2040440041 @default.
• W2171736612 cites W2046959088 @default.
• W2171736612 cites W2047207059 @default.
• W2171736612 cites W2067651948 @default.
• W2171736612 cites W2068102823 @default.
• W2171736612 cites W2093232733 @default.
• W2171736612 cites W2094965557 @default.
• W2171736612 cites W2102238081 @default.
• W2171736612 cites W2106343349 @default.
• W2171736612 cites W2109972098 @default.
• W2171736612 cites W2118001807 @default.
• W2171736612 cites W2126543805 @default.
• W2171736612 cites W2141941946 @default.
• W2171736612 cites W2142526970 @default.
• W2171736612 cites W2317179482 @default.
• W2171736612 cites W4238251256 @default.
• W2171736612 cites W4255876143 @default.
• W2171736612 doi "https://doi.org/10.1002/phar.1351" @default.
• W2171736612 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24734312" @default.
• W2171736612 hasPublicationYear "2013" @default.
• W2171736612 type Work @default.
• W2171736612 sameAs 2171736612 @default.
• W2171736612 citedByCount "24" @default.
• W2171736612 countsByYear W21717366122014 @default.
• W2171736612 countsByYear W21717366122015 @default.
• W2171736612 countsByYear W21717366122016 @default.
• W2171736612 countsByYear W21717366122017 @default.
• W2171736612 countsByYear W21717366122018 @default.
• W2171736612 countsByYear W21717366122019 @default.
• W2171736612 countsByYear W21717366122020 @default.
• W2171736612 countsByYear W21717366122021 @default.
• W2171736612 crossrefType "journal-article" @default.
• W2171736612 hasAuthorship W2171736612A5021831441 @default.
• W2171736612 hasAuthorship W2171736612A5030855173 @default.
• W2171736612 hasAuthorship W2171736612A5037375815 @default.
• W2171736612 hasAuthorship W2171736612A5075555151 @default.
• W2171736612 hasAuthorship W2171736612A5079278801 @default.
• W2171736612 hasAuthorship W2171736612A5086571286 @default.
• W2171736612 hasAuthorship W2171736612A5086951622 @default.
• W2171736612 hasConcept C112705442 @default.
• W2171736612 hasConcept C126322002 @default.
• W2171736612 hasConcept C134018914 @default.
• W2171736612 hasConcept C2776329913 @default.
• W2171736612 hasConcept C2776839432 @default.
• W2171736612 hasConcept C2777482532 @default.
• W2171736612 hasConcept C2778110834 @default.
• W2171736612 hasConcept C2778163477 @default.
• W2171736612 hasConcept C2778657065 @default.
• W2171736612 hasConcept C2779120738 @default.
• W2171736612 hasConcept C2780072125 @default.
• W2171736612 hasConcept C2780092750 @default.
• W2171736612 hasConcept C2780499067 @default.
• W2171736612 hasConcept C2780948078 @default.
• W2171736612 hasConcept C43554185 @default.
• W2171736612 hasConcept C71924100 @default.
• W2171736612 hasConcept C98274493 @default.
• W2171736612 hasConceptScore W2171736612C112705442 @default.
• W2171736612 hasConceptScore W2171736612C126322002 @default.
• W2171736612 hasConceptScore W2171736612C134018914 @default.
• W2171736612 hasConceptScore W2171736612C2776329913 @default.
• W2171736612 hasConceptScore W2171736612C2776839432 @default.
• W2171736612 hasConceptScore W2171736612C2777482532 @default.
• W2171736612 hasConceptScore W2171736612C2778110834 @default.
• W2171736612 hasConceptScore W2171736612C2778163477 @default.
• W2171736612 hasConceptScore W2171736612C2778657065 @default.
• W2171736612 hasConceptScore W2171736612C2779120738 @default.
• W2171736612 hasConceptScore W2171736612C2780072125 @default.
• W2171736612 hasConceptScore W2171736612C2780092750 @default.
• W2171736612 hasConceptScore W2171736612C2780499067 @default.
• W2171736612 hasConceptScore W2171736612C2780948078 @default.
• W2171736612 hasConceptScore W2171736612C43554185 @default.
• W2171736612 hasConceptScore W2171736612C71924100 @default.
• W2171736612 hasConceptScore W2171736612C98274493 @default.
• W2171736612 hasIssue "3" @default.
• W2171736612 hasLocation W21717366121 @default.
• W2171736612 hasLocation W21717366122 @default.
• W2171736612 hasOpenAccess W2171736612 @default.
• W2171736612 hasPrimaryLocation W21717366121 @default.

• next